Dow to Buy Wolff Walsrode, Cellulosics Supplier
The Dow Chemical Company (Midland, MI) has agreed to acquire Wolff Walsrode, a manufacturer of cellulose products and a business unit of the Bayer Group (Leverkusen, Germany, www.bayer.com).
Midland, MI (Dec. 18)
-The Dow Chemical Company (
www.dow.com
) has agreed to acquire Wolff Walsrode, a manufacturer of cellulose products and a business unit of the Bayer Group (Leverkusen, Germany,
www.bayer.com
).
Wolff Walsrode, with 2005 revenues of more than $400 million, will become part of Dow's water-soluble polymers business. The new business combines Wolff's production technology and product expertise in hydroxyethyl methyl cellulose and carboxymethyl cellulose with Dow's position in hydroxypropyl methyl cellulose. Cellulose derivatives are used in various applications, including as excipients in pharmaceuticals and in other products such as food, personal care, and other specialty applications.
The deal is expected to close in the first half of 2007, subject to regulatory approval. Financial terms were not disclosed.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
